{
    "clinical_study": {
        "@rank": "112713", 
        "arm_group": {
            "arm_group_label": "Asunaprevir + Daclatasvir", 
            "arm_group_type": "Experimental", 
            "description": "Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and\nDaclatasvir 60mg tablet by mouth once daily for 24 weeks"
        }, 
        "brief_summary": {
            "textblock": "Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon\n      alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV)\n      Dual regimen (= Daclatasvir + Asunaprevir) and followed for an additional 24 weeks\n      post-treatment in order to determine the safety and efficacy of the DCV DUAL regimen"
        }, 
        "brief_title": "Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Males and females, \u2265 18 years of age\n\n          -  Subjects chronically infected with HCV Genotype (GT)-1b only as documented by\n             positive HCV RNA and anti-HCV antibody at screening and either:\n\n               1. Positive anti-HCV antibody, HCV RNA or positive HCV genotype test at least 6\n                  months prior to screening\n\n                  or\n\n               2. Liver biopsy consistent with chronic HCV infection (evidence of fibrosis and/or\n                  inflammation)\n\n          -  Subjects who are intolerant to previous therapy with Interferon Alfa (IFN\u03b1) either\n             with or without Ribavirin (RBV) (I\u00b1R)(independent of previous response to therapy) or\n             ineligible for I\u00b1R and who meet one of the criteria below:\n\n               1. Anemia: the I\u00b1R intolerants are subjects who were previously treated with\n                  IFN\u03b1/RBV therapy and had a decline in hemoglobin to < 8.5 g/dL during therapy\n                  (documented); the I\u00b1R ineligibles are subjects who have a screening hemoglobin <\n                  10.0 g/dL and \u2265 8.5 g/dL\n\n                  OR\n\n               2. Neutropenia: the I\u00b1R intolerants are subjects who were previously treated with\n                  IFN\u03b1/RBV therapy and had a decline in absolute neutrophil count (ANC) to < 0.5 x\n                  10(9) during therapy (documented); the I\u00b1R ineligibles are subjects who have a\n                  screening ANC < 1.5 x 10(9) cells/L and \u2265 0.5 x 10(9) cells/L\n\n                  OR\n\n               3. Thrombocytopenia: the I\u00b1R intolerants are subjects who were previously treated\n                  with IFN\u03b1/RBV therapy and had a decline in platelet counts < 25,000 cells/mm3\n                  during therapy (documented); the I\u00b1R ineligibles are subjects who have a\n                  screening platelet count of < 90 x 10(9) cells/L and \u2265 50 x 10(9) cells/L\n\n          -  HCV RNA \u2265 10,000 IU/mL\n\n          -  Seronegative for Human Immunodeficiency Virus (HIV) and hepatitis B surface antigen\n             (HBsAg)\n\n          -  Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive. BMI = weight (kg)/ [height(m)]2\n             at screening\n\n          -  Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped\n             at approximately 40%). If a subject does not have cirrhosis, a liver biopsy within\n             three years prior to enrollment is required to demonstrate the absence of cirrhosis.\n             If cirrhosis is present, any prior liver biopsy is sufficient. For countries where\n             liver biopsy is not required prior to treatment and where noninvasive imaging tests\n             (Fibroscan\u00ae ultrasound) are approved for staging of liver disease, non-invasive\n             imaging test results may be used to assess the extent of liver disease\n\n        Exclusion Criteria:\n\n          -  Prior treatment with HCV direct acting antiviral (DAA)\n\n          -  Evidence of a medical condition contributing to chronic liver disease other than HCV\n\n          -  Evidence of decompensated liver disease including, but not limited to, a history or\n             presence of ascites, bleeding varices, or hepatic encephalopathy\n\n          -  Diagnosed or suspected hepatocellular carcinoma or other malignancies\n\n          -  Uncontrolled diabetes or hypertension\n\n          -  History of moderate to severe depression. Well-controlled mild depression is allowed\n\n          -  Total bilirubin \u2265 34 \u00b5mol/L (or \u2265 2 mg/dL) unless subject has a documented history of\n             Gilbert's disease\n\n          -  Confirmed alanine aminotransferase (ALT) \u2265 5 x upper limit of normal (ULN)\n\n          -  Confirmed albumin < 3.5 g/dL (35 g/L)\n\n          -  Alpha-fetoprotein (AFP) > 100 ng/mL OR \u2265 50 and \u2264 100 ng/mL requires a liver\n             ultrasound and subjects with findings suspicious of hepatocellular carcinoma (HCC)\n             are excluded\n\n          -  Confirmed hemoglobin < 8.5 g/dL\n\n          -  Confirmed ANC < 0.5 x 10(9) cells/L\n\n          -  Confirmed platelet count < 50,000 cells/mm3"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995266", 
            "org_study_id": "AI447-036"
        }, 
        "intervention": [
            {
                "arm_group_label": "Asunaprevir + Daclatasvir", 
                "intervention_name": "Asunaprevir", 
                "intervention_type": "Drug", 
                "other_name": "BMS-650032"
            }, 
            {
                "arm_group_label": "Asunaprevir + Daclatasvir", 
                "intervention_name": "Daclatasvir", 
                "intervention_type": "Drug", 
                "other_name": "BMS-790052"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interferons"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 23, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Site 0001"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100034"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0021"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100050"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0010"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100015"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0039"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100054"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0014"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510060"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0012"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510515"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0013"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510630"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0028"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430022"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410011"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410008"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0030"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0007"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210003"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0020"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210002"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0009"
                }, 
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "state": "Jilin", 
                        "zip": "130021"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning", 
                        "zip": "110000"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0008"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200025"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0031"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200235"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0026"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "400010"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0024"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300192"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0023"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100039"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0029"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "400038"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0017"
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "zip": "710038"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0025"
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "zip": "710061"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0034"
                }, 
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-715"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0035"
                }, 
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "700-712"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0037"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "140-743"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0036"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3, Open-Label Study With Daclatasvir And Asunaprevir (DUAL) for Subjects With Genotype 1b Chronic Hepatitis C (HCV) Infection Who Are Intolerant or Ineligible to Interferon Alfa Therapies With or Without Ribavirin", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Korea: Food and Drug Administration", 
                "Taiwan: Department of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "SVR24 is defined as hepatitis C virus (HCV) RNA < lower limit of quantification (LLOQ) target detected or not detected at post-treatment follow-up week 24 after treatment from baseline to up to 24 weeks", 
            "measure": "Proportion of treated subjects who achieve Sustained Virologic Response (SVR) 24", 
            "safety_issue": "No", 
            "time_frame": "At Post-treatment follow-up week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995266"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < LLOQ target detected or not detected at post-treatment follow-up week 12 after treatment from baseline to up to 24 weeks", 
                "measure": "Proportion of treated subjects who achieve SVR12", 
                "safety_issue": "No", 
                "time_frame": "At Post-treatment follow-up week 12"
            }, 
            {
                "description": "On-treatment safety is measured by the frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs) from baseline to up to 24 weeks EOT plus 7 days", 
                "measure": "Safety, as measured by the frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks end of treatment (EOT) + 7 days"
            }, 
            {
                "measure": "Proportion of subjects who achieve SVR24 by the rs12979860 single nucleotide polymorphism (SNP) in the Interferon lambda 3 (IL28B) gene", 
                "safety_issue": "No", 
                "time_frame": "At Post-treatment follow-up week 24"
            }, 
            {
                "measure": "Proportion of subjects with HCV RNA target not detected", 
                "safety_issue": "No", 
                "time_frame": "On treatment weeks 1,2,4,6,8 and 12; at both weeks 4 and 12 extended rapid virologic response (eRVR); at EOT (up to 24 weeks), post-treatment weeks 12 or 24"
            }, 
            {
                "measure": "Proportion of subjects with HCV RNA < LLOQ target detected or not detected", 
                "safety_issue": "No", 
                "time_frame": "On treatment weeks 1,2,4,6,8 and 12; at both weeks 4 and 12 Virologic Response (VR); Up to 24 weeks"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}